Detalhe da pesquisa
1.
The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
Toxicol Appl Pharmacol
; 485: 116911, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38527694
2.
Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs.
Pharmacol Res
; 190: 106724, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36907287
3.
Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.
Biomed Chromatogr
; 37(11): e5720, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596864
4.
ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability.
Pharmacol Res
; 178: 106137, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192958
5.
A robust, accurate, sensitive LC-MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells.
Biomed Chromatogr
; 36(5): e5307, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978088
6.
Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Biomed Chromatogr
; 36(11): e5457, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855648
7.
Extrahepatic metabolism of ibrutinib.
Invest New Drugs
; 39(1): 1-14, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32623551
8.
ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Pharmacol Res
; 172: 105850, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34450308
9.
Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
Pharmacol Res
; 146: 104297, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175939
10.
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Int J Cancer
; 143(8): 2029-2038, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29744867
11.
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
Mol Pharm
; 15(11): 5124-5134, 2018 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30247919
12.
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Pharmacol Res
; 137: 47-55, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30253203
13.
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
Pharmacol Res
; 129: 414-423, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29155017
14.
Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Pharm Res
; 35(4): 85, 2018 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29516187
15.
Quantification of cystine in human renal proximal tubule cells using liquid chromatography-tandem mass spectrometry.
Biomed Chromatogr
; 32(8): e4238, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29517154
16.
Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Mol Pharm
; 14(10): 3258-3268, 2017 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28880088
17.
Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
Pharmacol Res
; 120: 43-50, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28288939
18.
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Pharmacol Res
; 102: 200-7, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26361725
19.
Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Pharm Res
; 32(7): 2205-16, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25563977
20.
Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Pharm Res
; 32(1): 37-46, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24962512